The effects of tamsulosin, a high affinity antagonist at functional α(1A)- and α(1D)-adrenoceptor subtypes

British Journal of Pharmacology

Volumn 120, Issue 2, 1997, Pages 231-238

  Noble, A J ^a   Chess Williams, R ^a   Couldwell, C ^a   Furukawa, K ^b   Uchyiuma, T ^b   Korstanje, C ^c   Chapple, C R ^d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ASTELLAS PHARMA INC   (Japan)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

1 adrenoceptors; Aorta; Corpus cavernosum; Prostate; Receptor subtypes; Spleen; Tamsulosin; Vas deferens

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PHENYLEPHRINE; POTASSIUM CHLORIDE; RECEPTOR SUBTYPE; SEROTONIN; TAMSULOSIN;

ANIMAL TISSUE; AORTA; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS CAVERNOSUM; DEPOLARIZATION; HUMAN; HUMAN TISSUE; INCUBATION TIME; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; RABBIT; RECEPTOR AFFINITY; SPLEEN; VAS DEFERENS;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MIDDLE AGED; PROSTATE; RABBITS; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; SULFONAMIDES; VAS DEFERENS;

EID: 0031037284     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0700907     Document Type: Article

References (35)

1. ABRAMS, P., SCHULMAN, C.C. & VAAGE, S. (1995). The efficacy and safety of 0.4 mg tamsulosin once daily in symptomatic BPH. Procs. Am. Urol. Assoc., 153, (Suppl.) 274A.
2. ARUNLAKSHANA, O. & SCHILD, H.O. (1959). Some quantitative uses of drug antagonists. Br. J. Pharmacol. Chemother., 14, 48-58.
3. 1B-adrenoceptor mediating contraction of the rat spleen. Br. J. Pharmacol., 115, 467-475.
4. 1-adrenoceptor selectivity. Br. J. Urol., 76, Suppl. 1, 47-55.
5. 1-adrenoceptor. Br. J. Pharmacol., 119, 1093-1100.
6. DONKER, P.J., IVANOVICI, F. & NOACH, E.L. (1972). Analyses of the urethral pressure profile by means of electromyography and the administration of drugs. Br. J. Urol., 44, 180-193.
7. 1-Adrenoceptor subclassification in vascular smooth muscle. Trends Pharmacol. Sci., 7, 347-349.
8. 1-adrenoceptors to characterise subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur. J. Pharmacol., 288, 201-207.
9. FORD, A.P.D.W., ARREDONDO, N.F., BLUE, D.R., BONHAUS, D.W., JASPER, J., KAVA, M.S., LESNICK, J., PFISTER, J.R., SHIEH, I.A., VIMONT, R.L., WILLIAMS, T.L., MCNEAL, J.E., STAMEY, T.A. & CLARKE, D.E. (1996a). RS17053 (N-[2-(2-cyclopropyl-methoxyphenoxy)ethyl]-5-chloro-alpha,alpha-dimethyl-1H- indole-3-ethanamine hydrochloride), a selective alpha(1A)-adrenoceptor antagonist, displays low affinity for functional alpha1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol. Pharmacol., 49, 209-215.
10. 1A-adrenoceptor? Br. J. Pharmacol., 118, 29P.
11. 1-Adrenoceptor classification: sharpening Occam's razor. Trends Pharmacol. Sci., 15, 167-170.
12. 1c subtype. Mol. Pharmacol., 45, 703-709.
13. 1B-adrenoceptor subtype-mediating the phenylephrine-induced contractile response in rabbit corpus cavernosum penis. Jap. J. Pharmacol., 71, 325-331.
14. 1A-Adrenoceptor mediated contracile responses of the human vas deferens. Br. J. Pharmacol., 116, 1605-1610.
15. FURUYA, S., KUMAMOTO, Y., YOKOYAMA, E., TSUKAMOTO, T., IZUMI, T. & ABIKO, Y. (1982). Alpha-adrenergic activity and urethral pressure profilometry in prostatic zone in benign prostatic hypertrophy. J. Urol., 128, 836-839.
16. HAN, C., HOLLINGER, S., THEROUX, T.L., ESBENSHADE, T.A. & MINNEMAN, K.P. (1995). 3H-Tamsulosin binding to cloned α1-adrenergic receptor subtypes expressed in human embryonic kidney 293 cells: antagonist potencies & sensitivity to alkylating agents. Pharmacol. Commun., 5, 117-126.
17. 1 adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br. J. Pharmacol., 113, 723-728.
18. 1-adrenoceptors: consensus update. Pharmacol. Rev., 47, 267-270.
19. HIEBLE, J.P., CAINE, M. & ZALAZNIK, E. (1985). In vitro characterization of the a adrenoceptors in human prostate. Eur. J. Pharmacol., 107, 111-117.
20. 1c-adrenoceptor splice variants. FEBS Letts., 363, 256-260.
21. KAWABE, K. (1995). Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Br. J. Urol., 76, (Suppl. 1), 63-67.
22. 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br. J. Pharmacol., 115, 981-986.
23. 1-adrenoceptor antagonists on prostatic pressure and blood pressure in the anaesthetised dog. Urology, 44, 52-57.
24. 1c-antagonist. J. Urol., 153, 182.
25. 1C-)adrenoceptor subtype. Br. J. Pharmacol., 115, 781-786.
26. 1-Adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Naunyn-Schmiedeberg's Arch. Pharmacol., 348, 385-395.
27. 1-adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch. Pharmacol., 350, 136-142.
28. 1-adrenoceptors. Pharmacol. Commun., 6, 23-28.
29. PRICE, D.T., SCHWINN, D.A., LOMASNEY, J.W., ALLEN, L.F., CARON, M.G. & LEFKOWITZ, R.J. (1993). Identification, quantification, and localization of mRNA for three distinct α1-adrenergic receptor subtypes in human prostate. J. Urol., 150, 546-551.
30. 1-adrenergic receptor subtypes in BPH determined by reverse transcriptase PCR. Soc. Int. Urol. Proc., A648.
31. 1a/d subtypes. Soc. Int. Urol. Proc., A678.
32. 1-antagonist selective for the lower urinary tract: in vitro studies. Neurourol. Urodynam., 13, 473-474.
33. 1-antagonist selective for the lower urinary tract: in vivo studies. Neurourol. Urodynam., 13, 471-473.
34. 1-adrenoceptors in the rat aorta. Br. J. Pharmacol., 110, 124P.
35. 1-antagonists. Life Sci., 54, 1845-1854.